Declining non-permanent residents, natural decrease (less births than deaths) and softer immigration inflows have placed Canada in period of demographic contraction. For the first time ever, Canada experienced a population decline. Ultimately, our population decline is due to our own choices as our government tried to compensate for disastrous immigration policy under Justin Trudeau's Liberal Party.
Gordon Lam
As seen in:
Hashtag Legend,
LinkedIn,
Color Research & Application,
MDPI,
Medscape,
Healio,
NewsBreak,
HCP Live
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Gordon Lam
Elderly Hip Osteoarthritis: A Review of Short-Term Pain Relief Through Non-Weight-Bearing Therapies
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Closing Remarks
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 16 Published on: , , , , Panelists discuss how their approaches to treating patients with rheumatoid arthritis focus on personalized strategies that prioritize achieving remission while carefully monitoring safety and efficacy outcomes. Video content above is prompted by the following: Can each of you provide closing remarks on how you treat your own patients to achieve remission?
Safety and Efficacy of Janus Kinase Inhibitors
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 15 Published on: , , , , Panelists discuss how the findings from the ORAL Surveillance study regarding cardiovascular and cancer risks associated with tofacitinib have influenced perceptions of JAK inhibitors, emphasizing the need to balance safety concerns with their efficacy in managing rheumatoid arthritis.
Cycling Within TNF Inhibitors: Complications and Factors Influencing Treatment Choices
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 14 Published on: , , , , Panelists discuss how continued cycling of tumor necrosis factor inhibitors (TNFis) without achieving remission can lead to complications like irreversible joint erosion, significantly diminishing patient quality of life, and explore why providers may persist with TNFis despite failure, access barriers to switching mechanisms of action, and treatment considerations for...
Outcomes of Class Switching vs Cycling TNF Inhibitors
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 13 Published on: , , , , Panelists discuss how switching to a biologic with a different mechanism of action can enhance clinical outcomes in patients with inadequate responses to tumor necrosis factor inhibitors.
JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 11 Published on: , , , , Panelists discuss how JAK inhibitors and TNF inhibitors differ in administration, efficacy, and safety due to their unique characteristics and mechanisms of action, with further variations in binding activities within the TNFi class impacting clinical outcomes.
JAK Inhibitor Selectivity and Dose-Related Toxicity
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 12 Published on: , , , , Panelists discuss how the varying selectivity of JAK inhibitors—such as tofacitinib's broad inhibition of JAK1/JAK2/JAK3, baricitinib's inhibition of JAK1/JAK2, and upadacitinib's focus on JAK1—affects dose-related toxicity and overall treatment safety.
Advanced Treatment Options for RA: Exploring the Data
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 9 Published on: , , , , Panelists discuss advanced treatment options for rheumatoid arthritis, focusing on the SELECT-COMPARE trial's head-to-head data of upadacitinib versus adalimumab, the use of upadacitinib in active RA refractory to biologics (SELECT-BEYOND trial), and the remission rates of upadacitinib compared to abatacept (SELECT-CHOICE trial).
Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 10 Published on: , , , , Panelists discuss how head-to-head clinical trial data shape their treatment decisions, the significance of consistent remission rates across different patient populations, and the frequency with which remission data influence their choices to switch therapies. Video content above is prompted by the following: How do head-to-head data affect your treatment decisions?
Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies
By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy It’s essential to note our commitment to transparency: Our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies.
Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 8 Published on: , , , , Experts discuss American College of Rheumatology guidelines on transitioning patients from TNF inhibitors to non-TNF targeted therapies like Janus kinase inhibitors, as well as factors influencing treatment switching decisions in clinical practice.
Achieving Low Disease Activity and Remission: Managing Patient Expectations
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 7 Published on: , , , , Experts discuss strategies for achieving low disease activity or remission in patients, including steps taken in clinical practice and methods for managing patient expectations regarding treatment outcomes. Video content above is prompted by the following: In your practice, what steps do you take to ensure your patients reach low disease activity, and/or remission?
Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies
By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy It’s essential to note our commitment to transparency: Our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies.
Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 5 Published on: , , , , A panel of medical experts explore how to evaluate and adjust rheumatoid arthritis treatment by adhering to ACR guidelines for conventional synthetic DMARDs and advanced therapies, focusing on optimizing patient care and treatment outcomes.
Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 6 Published on: , , , , Medical experts explore how patient perceptions of rheumatoid arthritis can differ from disease activity assessments and provide an example of hidden symptoms revealed through further probing, along with the impact of therapy adjustments on achieving remission.
Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis
By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy It’s essential to note our commitment to transparency: Our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies.
Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 3 Published on: , , , , A panel of medical experts discuss the prevalence and management of poorly controlled rheumatoid arthritis in clinical practice. Video content above is prompted by the following: As we know, many patients do not reach clinical remission and experience uncontrolled disease and progression. In your practice, how frequently do you see poorly controlled rheumatoid arthritis?
Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 3 Published on: , , , , A panel of medical experts discuss how clinical guidelines currently define clinical remission, as well as the clinical and economic benefits associated with clinical remission. Over the past few years, the goal of rheumatoid arthritis treatment has evolved from relieving symptoms to achieving clinical remission, which inhibits radiologic damage and prevents disability. 1.
Intro and Welcomes
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 2 Intro and Welcomes Published on: August 8, 2024 Gordon Lam, MD, Leonard Calabrese, DO, Grace Wright, MD, PhD, Jeffrey A. Sparks, MD, MMSc, Catherine Bakewell, MD A panel of medical experts introduce themselves before diving into a discussion about remission achievement in rheumatoid arthritis.
The Panerai Experience Watch Programme in Rome
Privacy Overview This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies.
Discovering the spirit of The Macallan (part 2)
The story of The Macallan begins in Jerez de la Frontera, Spain, and concludes in Speyside, Scotland. Gordon Lam shares his two-part journey of discovery into the making of the brand’s legendary single malts Chapter 2: The Macallan Distillery, Speyside, Scotland Bidding farewell to everyone in Jerez de la Frontera was indeed a sad moment. The following morning we departed Spain and headed onwards to Scotland.
Discovering the spirit of The Macallan (part 1)
The story of The Macallan begins in Jerez de la Frontera, Spain, and concludes in Speyside, Scotland. Gordon Lam shares his two-part journey of discovery into the making of the brand’s legendary single malts I can’t say I’m a connoisseur of whisky. In fact, I hardly drink the stuff.
A dream drive in the Maserati GranTurismo — Hashtag Legend
The Maserati GranTurismo has been described as ‘more than a car, it’s a lifestyle’. Gordon Lam journeys 400 km through the Italian countryside and across 75 years of history to find out why The Maserati GranTurismo has been my favourite car of all time since it came out in 2007. I happen to own one of the first-generation production versions, with the 4.2-liter V8 Ferrari-derived F430 engine, which even today drives like a dream and roars like a beast.
Experiencing Jaeger-LeCoultre's craftsmanship - Hashtag Legend
Home to the most important watchmaking manufacture in the legendary Vallée de Joux, Jaeger-LeCoultre has been at the forefront of its industry since 1833. Gordon Lam visits its hallowed grounds and comes away with a newfound appreciation for innovation, precision and craftsmanship After four days at Watches and Wonders, covering more than 20 different watch brands, it was finally time to relax, wind down and enjoy the best watchmaking the world has to offer.
Van Cleef & Arpels heads to Rome for Le Grand Tour High Jewellery Collection — Hashtag Legend
Van Cleef & Arpels travelled back to 18th-century Europe to inspire its latest high jewellery collection. Gordon Lam joins the maison on a dazzling journey to Rome to learn more about Le Grand Tour When it comes to a global launch event, few brands can even come close to matching the hospitality and showmanship of Van Cleef & Arpels. The last event put on by the maison that I had the pleasure to attend was in pre-COVID times, a celebration of the Alhambra Collection in Marrakesh.
Maserati’s Grecale SUV gets the green light — Hashtag Legend
Looks, power, comfort and performance – Maserati’s Grecale SUVs have it all. Gordon Lam rediscovers his passion for the best-in-class series with the first test drive of the new Maserati Grecale Modena The Maserati Grecale Modena was designed to embody the concepts of innovation, versatility and luxury, striking the perfect balance between sportiness and elegance. Ever since its launch in 2016 as the Italian luxury car brand’s first SUV, the Maserati Levante has always caught my eye.
#review: Lamborghini’s road-legal Huracán STO — Hashtag Legend
Gordon Lam’s birthday wishes come true behind the wheel of Lamborghini’s road-legal Huracán STO What better way to kick-start my birthday month than by celebrating with two of my favourite brands, Lamborghini and Roger Dubuis? It goes without saying that these two brands’ collaboration is still going strong.
Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?
vaccination COVID-19 biological therapy methotrexate arthritis, rheumatoid Clinical trials leading to approval of the COVID-19 vaccines did not include immunocompromised individuals. Concerns have been raised that immunogenicity of the vaccines may be impaired in patients with autoimmune and inflammatory rheumatic disease (AIIRD) on immunomodulatory drugs. In December of 2020, our clinic recommended adjustments to the dosing/timing of select drugs to attempt to optimise vaccine response.
Most rheumatologists 'unlikely' to switch to biosimilars until greater payer adoption
February 23, 2022 4 min read Save Source/Disclosures ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Most rheumatologists say COVID-19 pandemic exposed mental health as 'key unmet need'
November 03, 2021 3 min read Save ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Organ transplant recipients 'should not assume immunity' from COVID-19 vaccine
May 13, 2021 4 min read Save Perspective from Source/Disclosures Published by: Disclosures: Boyarsky reports grant support from the Ben-Dov family. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later.
Switching Between Reference and Biosimilar Infliximab
Table 1. Biosimilar TNF blockers currently approved by the US FDA 8, 9 Reference product Biosimilar Synonyms Date of FDA approval Infliximab Infliximab-dyyb CT-P13 5 April 2016 Infliximab-abda SB2 21 April 2017 Infliximab-qbtx PF-06438179, GP1111 13 December 2017 Adalimumab Adalimumab-atto ABP 501 23 September 2016 Adalimumab-adbm BI 695501 25 August 2017 Etanercept Etanercept-szzs GP2015 30 August 2016 FDA, Food and Drug Administration; TNF, tumour-necrosis factor. Table 2.
Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
Summary Background Biosimilar versions of widely prescribed drugs, including the tumour‐necrosis factor antagonist infliximab, are becoming increasingly available. As biosimilars are not identical copies of reference products, evidence may be required to demonstrate that switching between a reference biologic and biosimilars is safe and efficacious.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Gordon
Contact Gordon, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack